The State of HIV/AIDS Progress and Applying Lessons Learned to Current Public Health Emergencies
JOIN THE CONVERSATION

@AllHealthPolicy

Alliance for Health Policy

@AllianceforHealthPolicy

#AllHealthLive
To mute yourself, click the microphone icon. The icon will appear orange when muted.

To ask a question, click the ? icon and enter your question in the chat box below.
Anand Parekh, M.D., MPH
Chief Medical Advisor
Bipartisan Policy Center

@AParekhBPC
SPEAKERS

Lindsey Dawson, MPP
Associate Director of HIV Policy & Director of LGBTQ Health Policy
Kaiser Family Foundation (KFF)
@LindseyH_Dawson

Antoinette Jones
HIV Public Speaker and Advocate
Positive Women’s Network
@uspwn

Amesh Adalja, M.D.
Senior Scholar, Center for Health Security
Johns Hopkins Bloomberg School of Public Health
@AmeshAA

Anand Parekh, M.D., MPH
Chief Medical Advisor
Bipartisan Policy Center
@AParekhBPC

Moderator
Lindsey Dawson, MPP
Associate Director of HIV Policy; Director of LGBTQ Health Policy
Kaiser Family Foundation (KFF)

@LindseyH_Dawson
The State of HIV/AIDS Progress & Applying Lessons Learned to Current Public Health Emergencies

Lindsey Dawson
Presentation to: Alliance for Health Policy

October 12, 2022
ldawson@kff.org
Snapshot of the U.S. HIV Epidemic

1981-Present
An evolving epidemic

1.2 million
People living with HIV and living longer

About 35K new infections/yr
8% decline 2015 - 2019, previously stable

Disparities persist
Black Americans + Latinos
The South
Gay/Bisexual Men + Transgender Women

New prevention options
PrEP, TasP
HIV Care Continuum, 2019

- **Diagnosed**: 87%
- **Receiving Care**: 66%
- **Retained in Care**: 50%
- **Virally Suppressed**: 57%

49% in 2014

HIV Viral Suppression Rate in U.S. Lowest Among Comparable High-Income Countries, 2020 or Latest Year

Rates of Viral Suppression Among People with HIV, by Country

<table>
<thead>
<tr>
<th>Country</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Switzerland</td>
<td>89%</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>87%</td>
</tr>
<tr>
<td>Sweden</td>
<td>86%</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>82%</td>
</tr>
<tr>
<td>Australia</td>
<td>80%</td>
</tr>
<tr>
<td>Belgium</td>
<td>78%</td>
</tr>
<tr>
<td>Germany</td>
<td>77%</td>
</tr>
<tr>
<td>France</td>
<td>73%</td>
</tr>
<tr>
<td>Canada</td>
<td>70%</td>
</tr>
<tr>
<td>Austria</td>
<td>64%</td>
</tr>
<tr>
<td>United States</td>
<td>57%</td>
</tr>
</tbody>
</table>


NOTE: All data for 2020 except Canada which is for 2018 and U.S. which is for 2019.
Federal Funding for HIV Programs, in Billions

Federal Ryan White Funding FY1991-FY2022

Source: KFF analysis of data from OMB, congressional budget justifications, and appropriations bills
Notes: Funding adjusted using CPI-U [www.bls.gov]
Amesh Adalja, M.D.
Senior Scholar, Center for Health Security
*Johns Hopkins Bloomberg School of Public Health*
HIV Medicines Help People with HIV Live Longer
(AVERAGE YEARS OF LIFE)

HIV-free newborns

79 YEARS

A person with HIV diagnosed at age 30 on taking current HIV medicines

73 YEARS

A person with HIV diagnosed at age 20 on taking current HIV medicines

32 YEARS

**TABLE 1.** FDA-Approved Options for HIV Preexposure Prophylaxis (PrEP)\(^1-3\)

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>BRAND NAME</th>
<th>DOSE</th>
<th>ROUTE OF ADMINISTRATION</th>
<th>FREQUENCY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emtricitabine/tenofovir disoproxil fumarate (F/TDF)</td>
<td>Truvada</td>
<td>200 mg/300 mg</td>
<td>Oral</td>
<td>Once a day(†)</td>
</tr>
<tr>
<td>Emtricitabine/tenofovir alafenamide (F/TAF)</td>
<td>Descovy(‡)</td>
<td>200 mg/25 mg</td>
<td>Oral</td>
<td>Once a day</td>
</tr>
<tr>
<td>Cabotegravir (CAB-LA)</td>
<td>Apretude(§)</td>
<td>600 mg</td>
<td>Intramuscular injection</td>
<td>Every 2 months(§)</td>
</tr>
</tbody>
</table>
Next Advances

- New classes of drugs: maturation inhibitors
- Broadly neutralizing monoclonal antibodies
- Vaccines
- Cure
Antoinette Jones
HIV Public Speaker and Advocate
*Positive Women's Network*
TAKE OUR SURVEY

Please fill out the evaluation survey you will receive immediately after this presentation, or via email this afternoon!

www.allhealthpolicy.org
UPCOMING EVENT

October 19, 2022 | 12:00 PM - 1:30 PM ET

Exploring the Market Competition Ecosystem: Lessons Learned and Next Steps

Over the last few decades, horizontal and vertical consolidation within health care markets has become a pressing issue – with competing market forces driving this dynamic. While there is some bipartisan agreement on site-neutral payment policies and curbing anti-competitive practices in health care, it has been challenging to meaningfully address these dynamics. This event will: 1) discuss past and current trends in market consolidation ecosystem 2) explore current legislative and administrative policy levers and 3) identify lessons learned at the state and federal levels.
THANK YOU FOR ATTENDING!